September 24, 2015 8:48am
My question for this management team is this all you’ve got … after all these 9 months ... $2 M more is not material until "it" hits the books!
CLBS has received a $300 K contract from the National Institutes of Health's (NIH) National Cancer Institute (NCI) to wholly fund the first phase of a project for process optimization of its therapeutic agent targeting tumor-initiating cells (often referred to as cancer stem cells). T
The contract anticipates an additional $2 M in funding for the project should both the government and Caladrius agree to proceed at the conclusion of the first phase which is expected in June 2016. Hans Keirstead, PhD, Chief Science Officer is the principal investigator for the project.
The Bottom Line; Short dollars grants do add up but, are still insignificant in the greater scheme of cancer cell R&D. The could, a might or anticipates is all about when it hits the account - when it happens - that's material!
CLBS closed at $1.72 which was down -$0.14 on 146.1 K share volume <3 month average =358.4 K shares>. Still can’t seem to break the $2.00 past offering pricing. My question for this management team is this all you’ve got after all these months – you’ve had 9 months for the new ideas and contacts everyone thought you were bringing, other than a new corporate HQ?